Perceptive Advisors Llc Sells 3,400,000 Shares of Aldeyra Therapeutics, Inc (NASDAQ:ALDX) Stock

Aldeyra Therapeutics, Inc (NASDAQ:ALDX - Get Free Report) major shareholder Perceptive Advisors Llc sold 3,400,000 shares of the business's stock in a transaction that occurred on Thursday, April 3rd. The stock was sold at an average price of $1.42, for a total transaction of $4,828,000.00. Following the completion of the sale, the insider now directly owns 5,875,851 shares of the company's stock, valued at $8,343,708.42. This represents a 36.65 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Large shareholders that own more than 10% of a company's shares are required to disclose their sales and purchases with the SEC.

Aldeyra Therapeutics Price Performance

Shares of NASDAQ:ALDX traded up $0.02 during trading on Friday, reaching $1.91. The stock had a trading volume of 1,717,870 shares, compared to its average volume of 680,193. Aldeyra Therapeutics, Inc has a 52 week low of $1.14 and a 52 week high of $7.20. The business's 50-day moving average price is $5.54 and its 200 day moving average price is $5.26. The company has a debt-to-equity ratio of 0.18, a quick ratio of 6.80 and a current ratio of 6.80.

Aldeyra Therapeutics (NASDAQ:ALDX - Get Free Report) last posted its quarterly earnings data on Thursday, March 6th. The biotechnology company reported ($0.27) EPS for the quarter, missing analysts' consensus estimates of $0.03 by ($0.30). On average, equities analysts anticipate that Aldeyra Therapeutics, Inc will post -0.92 EPS for the current fiscal year.

Remove Ads

Institutional Inflows and Outflows

Large investors have recently bought and sold shares of the company. SG Americas Securities LLC raised its position in shares of Aldeyra Therapeutics by 14.4% during the fourth quarter. SG Americas Securities LLC now owns 22,365 shares of the biotechnology company's stock worth $112,000 after acquiring an additional 2,822 shares during the last quarter. Geode Capital Management LLC lifted its position in Aldeyra Therapeutics by 0.4% during the 4th quarter. Geode Capital Management LLC now owns 1,119,555 shares of the biotechnology company's stock valued at $5,588,000 after purchasing an additional 4,927 shares during the period. Wells Fargo & Company MN boosted its stake in shares of Aldeyra Therapeutics by 1.9% in the 4th quarter. Wells Fargo & Company MN now owns 393,654 shares of the biotechnology company's stock valued at $1,964,000 after purchasing an additional 7,348 shares during the last quarter. Captrust Financial Advisors grew its position in shares of Aldeyra Therapeutics by 89.3% during the 3rd quarter. Captrust Financial Advisors now owns 19,261 shares of the biotechnology company's stock worth $104,000 after buying an additional 9,087 shares during the period. Finally, Intech Investment Management LLC raised its stake in shares of Aldeyra Therapeutics by 62.7% during the fourth quarter. Intech Investment Management LLC now owns 23,806 shares of the biotechnology company's stock worth $119,000 after buying an additional 9,178 shares during the last quarter. Institutional investors and hedge funds own 59.71% of the company's stock.

Wall Street Analysts Forecast Growth

A number of research firms have recently commented on ALDX. HC Wainwright reissued a "buy" rating and issued a $10.00 price target on shares of Aldeyra Therapeutics in a research report on Friday, April 4th. BTIG Research lowered their price objective on Aldeyra Therapeutics from $11.00 to $9.00 and set a "buy" rating on the stock in a research report on Monday, April 7th.

Aldeyra Therapeutics Company Profile

Aldeyra Therapeutics is a clinical-stage biotechnology company focused on the development of novel therapies with the potential to improve the lives of patients with immune-mediated diseases. Two of the company's lead compounds, reproxalap and ADX-629, target reactive aldehyde species (RASP), which are elevated in ocular and systemic inflammatory disease, leading to elevated levels of cytokine release via activation of a broad array of inflammatory factors, including NF-κB, inflammasomes, and Scavenger Receptor A.